JSPR · Jasper Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $34.27M | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $63.10M | $55.82M | $51.78M | $34.63M | $15.88M | - |
| SG&A | $20.78M | $20.42M | $17.08M | $16.57M | $11.41M | $935.4K |
| Total Operating Expenses | $83.88M | $76.24M | $68.86M | $51.20M | $20.68M | - |
| D&A | $1.06M | $1.37M | $975.0K | $975.0K | $377.0K | - |
| Operating Income | ($83.88M) | ($76.24M) | ($68.86M) | ($51.20M) | ($36.83M) | ($935.4K) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | $2.0K | - | - | - | $38.5K |
| Net Income | ($75.80M) | ($71.27M) | ($64.47M) | ($37.69M) | ($30.64M) | ($590.7K) |
| EPS - Basic | ($3.95) | ($4.89) | ($6.18) | ($26.90) | - | - |
| EPS - Diluted | ($3.95) | ($4.89) | ($6.18) | ($26.90) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.69M | $71.64M | $86.89M | $38.25M | $84.70M | $770.1K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $6.22M | $4.03M | $4.15M | $1.77M | $3.92M | - |
| Current Assets | $34.65M | $75.81M | $88.94M | $41.73M | $87.83M | $921.6K |
| Total Assets | $35.78M | $79.90M | $94.89M | $48.36M | $93.65M | $101.26M |
| Current Liabilities | $13.20M | $15.24M | $12.37M | $7.07M | $8.02M | $269.5K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $31.63M | $18.23M | $16.45M | $12.37M | $24.14M | $3.77M |
| Stockholders' Equity | $4.15M | $61.67M | $78.44M | $35.99M | $69.52M | $5.00M |
| Retained Earnings | ($316.67M) | ($240.87M) | ($169.60M) | ($105.14M) | ($67.45M) | ($588.7K) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($77.16M) | ($62.60M) | ($52.07M) | ($45.86M) | ($33.68M) | ($641.0K) |
| Investing Cash Flow | $5.0K | ($532.0K) | ($267.0K) | ($576.0K) | ($2.43M) | $198.3K |
| Financing Cash Flow | $34.21M | $47.88M | $100.97M | $55.0K | $11.29M | - |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -211.9% | -89.2% | -67.9% | -77.9% | -32.7% | -0.6% |
| Return on equity | -1826.1% | -115.6% | -82.2% | -104.7% | -44.1% | -11.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.62 | 4.98 | 7.19 | 5.91 | 10.95 | 3.42 |
| Quick ratio | 2.62 | 4.98 | 7.19 | 5.91 | 10.95 | 3.42 |
| Cash ratio | 2.17 | 4.70 | 7.02 | 5.41 | 10.56 | 2.86 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 8.62 | 1.30 | 1.21 | 1.34 | 1.35 | 20.25 |
| Liabilities / Assets | 0.88 | 0.23 | 0.17 | 0.26 | 0.26 | 0.04 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 66d | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 8.5x | 5.1x | 1.1x | 1.5x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -10.0% | -10.7% | -34.5% | -39.0% | -3837.7% | - |
| Net income growth (YoY) | -6.4% | -10.6% | -71.1% | -23.0% | -5086.5% | - |
| EPS growth (YoY) | 19.2% | 20.9% | 77.0% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -93.3% | -21.4% | 118.0% | -48.2% | 1290.4% | 0.0% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Jasper Therapeutics against the 5 most active filers in the same SIC group.